NASDAQ:EDGE - Edge Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$1.12 -0.06 (-5.08 %)
(As of 06/19/2018 09:49 AM ET)
Previous Close$1.13
Today's Range$1.12 - $1.13
52-Week Range$0.84 - $17.77
Volume1,100 shs
Average Volume868,291 shs
Market Capitalization$32.18 million
P/E RatioN/A
Dividend YieldN/A
Edge Therapeutics logoEdge Therapeutics, Inc., a clinical-stage biotechnology company, discovers, develops, and seeks to commercialize hospital-based therapies for acute life-threatening neurological and other conditions. Its lead product includes EG-1962, a polymer-based microparticle used for the treatment of aneurysmal subarachnoid hemorrhage. The company is also developing EG-1964, as a prophylactic treatment for the management of chronic subdural hematoma to prevent recurrent bleeding on the surface of the brain; and EG-1965, for the prevention of post-operative atrial fibrillation. Edge Therapeutics, Inc. was founded in 2009 and is headquartered in Berkeley Heights, New Jersey.

Receive EDGE News and Ratings via Email

Sign-up to receive the latest news and ratings for EDGE and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations


Debt-to-Equity RatioN/A
Current Ratio2.35
Quick Ratio2.35


Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$2.02 per share
Price / Book0.55


EPS (Most Recent Fiscal Year)N/A
Net Income$-50,850,000.00
Net MarginsN/A
Return on Equity-85.64%
Return on Assets-59.31%


Outstanding Shares31,250,000

Edge Therapeutics (NASDAQ:EDGE) Frequently Asked Questions

What is Edge Therapeutics' stock symbol?

Edge Therapeutics trades on the NASDAQ under the ticker symbol "EDGE."

How were Edge Therapeutics' earnings last quarter?

Edge Therapeutics Inc (NASDAQ:EDGE) announced its earnings results on Tuesday, May, 1st. The biotechnology company reported ($0.67) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by $0.14. View Edge Therapeutics' Earnings History.

When is Edge Therapeutics' next earnings date?

Edge Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, July, 30th 2018. View Earnings Estimates for Edge Therapeutics.

What price target have analysts set for EDGE?

2 brokers have issued twelve-month target prices for Edge Therapeutics' stock. Their predictions range from $17.00 to $17.00. On average, they anticipate Edge Therapeutics' share price to reach $17.00 in the next year. View Analyst Ratings for Edge Therapeutics.

Who are some of Edge Therapeutics' key competitors?

Who are Edge Therapeutics' key executives?

Edge Therapeutics' management team includes the folowing people:
  • Mr. Brian A. Leuthner, Co-Founder, Chief Exec. Officer, Pres and Director (Age 53)
  • Dr. R. Loch MacDonald M.D., Ph.D., Co-Founder, Chief Scientific Officer and Director (Age 56)
  • Dr. Herbert J. Faleck D.O., Chief Medical Officer (Age 65)
  • Mr. Andrew Saik, Chief Financial Officer (Age 49)
  • Mr. Daniel Brennan, Chief Operating Officer (Age 50)

Has Edge Therapeutics been receiving favorable news coverage?

Headlines about EDGE stock have trended somewhat positive on Tuesday, Accern Sentiment Analysis reports. The research group identifies positive and negative media coverage by monitoring more than 20 million news and blog sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores nearest to one being the most favorable. Edge Therapeutics earned a coverage optimism score of 0.09 on Accern's scale. They also assigned media stories about the biotechnology company an impact score of 48.37 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.

Who are Edge Therapeutics' major shareholders?

Edge Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional investors include Sofinnova Ventures Inc (9.13%), BlackRock Inc. (3.77%), Wells Fargo & Company MN (0.36%), Algert Global LLC (0.36%) and Element Capital Management LLC (0.35%). Company insiders that own Edge Therapeutics stock include Albert N Marchio II, Brian A Leuthner, James J Loughlin, R Loch Macdonald and W Bradford Middlekauff. View Institutional Ownership Trends for Edge Therapeutics.

Which major investors are buying Edge Therapeutics stock?

EDGE stock was acquired by a variety of institutional investors in the last quarter, including Sofinnova Ventures Inc, BlackRock Inc., Algert Global LLC, Element Capital Management LLC and Wells Fargo & Company MN. Company insiders that have bought Edge Therapeutics stock in the last two years include James J Loughlin and W Bradford Middlekauff. View Insider Buying and Selling for Edge Therapeutics.

How do I buy shares of Edge Therapeutics?

Shares of EDGE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Edge Therapeutics' stock price today?

One share of EDGE stock can currently be purchased for approximately $1.18.

How big of a company is Edge Therapeutics?

Edge Therapeutics has a market capitalization of $32.18 million. Edge Therapeutics employs 38 workers across the globe.

How can I contact Edge Therapeutics?

Edge Therapeutics' mailing address is 300 Connell Drive Suite 4000, Berkeley Heights NJ, 07922. The biotechnology company can be reached via phone at 800-208-3343 or via email at [email protected]

MarketBeat Community Rating for Edge Therapeutics (EDGE)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  103 (Vote Outperform)
Underperform Votes:  113 (Vote Underperform)
Total Votes:  216
MarketBeat's community ratings are surveys of what our community members think about Edge Therapeutics and other stocks. Vote "Outperform" if you believe EDGE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe EDGE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 6/19/2018 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.